1/12
04:42 pm
iron
Disc Medicine Appoints Lisa Amaya Price, MBA as Chief Human Resources Officer [Yahoo! Finance]
Medium
Report
Disc Medicine Appoints Lisa Amaya Price, MBA as Chief Human Resources Officer [Yahoo! Finance]
1/12
04:30 pm
iron
Disc Medicine Appoints Lisa Amaya Price, MBA as Chief Human Resources Officer
Medium
Report
Disc Medicine Appoints Lisa Amaya Price, MBA as Chief Human Resources Officer
1/12
08:30 am
iron
Disc Medicine Highlights Recent Achievements and Key Business Objectives and Milestones for 2026
Low
Report
Disc Medicine Highlights Recent Achievements and Key Business Objectives and Milestones for 2026
1/11
04:26 pm
iron
What Investors Should Know About a $511K Disc Medicine Insider Sale and a 26% Stock Run [Yahoo! Finance]
Low
Report
What Investors Should Know About a $511K Disc Medicine Insider Sale and a 26% Stock Run [Yahoo! Finance]
1/8
08:42 am
iron
Disc Medicine (NASDAQ:IRON) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.
Medium
Report
Disc Medicine (NASDAQ:IRON) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.
1/7
08:30 am
iron
Disc Medicine to Present at the 44th Annual J.P. Morgan Healthcare Conference
Medium
Report
Disc Medicine to Present at the 44th Annual J.P. Morgan Healthcare Conference
1/5
06:07 am
iron
Disc Medicine: RALLY-MF Data Validates Pipeline Optionality [Seeking Alpha]
Low
Report
Disc Medicine: RALLY-MF Data Validates Pipeline Optionality [Seeking Alpha]
12/19
03:03 pm
iron
Disc Medicine (NASDAQ:IRON) had its "buy" rating reaffirmed by analysts at Cowen Inc.
Low
Report
Disc Medicine (NASDAQ:IRON) had its "buy" rating reaffirmed by analysts at Cowen Inc.
12/16
10:17 am
iron
Disc Medicine (NASDAQ:IRON) had its price target raised by analysts at Wells Fargo & Company from $91.00 to $109.00. They now have an "overweight" rating on the stock.
Low
Report
Disc Medicine (NASDAQ:IRON) had its price target raised by analysts at Wells Fargo & Company from $91.00 to $109.00. They now have an "overweight" rating on the stock.
12/11
10:33 pm
iron
Has Disc Medicine's 2025 Surge Already Gone Too Far After Pipeline Progress Fuels Rally? [Yahoo! Finance]
Medium
Report
Has Disc Medicine's 2025 Surge Already Gone Too Far After Pipeline Progress Fuels Rally? [Yahoo! Finance]
12/8
10:13 am
iron
Disc Medicine (NASDAQ:IRON) had its "strong-buy" rating reaffirmed by analysts at Raymond James Financial, Inc..
Medium
Report
Disc Medicine (NASDAQ:IRON) had its "strong-buy" rating reaffirmed by analysts at Raymond James Financial, Inc..
12/6
08:00 am
iron
Disc Medicine Presents Positive Initial Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 67th American Society of Hematology (ASH) Annual Meeting
Low
Report
Disc Medicine Presents Positive Initial Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 67th American Society of Hematology (ASH) Annual Meeting
11/10
12:06 pm
iron
Disc Medicine (NASDAQ:IRON) had its price target raised by analysts at Truist Financial Corporation from $86.00 to $114.00. They now have a "buy" rating on the stock.
Low
Report
Disc Medicine (NASDAQ:IRON) had its price target raised by analysts at Truist Financial Corporation from $86.00 to $114.00. They now have a "buy" rating on the stock.
11/8
07:05 pm
iron
What Disc Medicine (IRON)'s Bitopertin Fast-Track Review and Rising R&D Spend Mean for Shareholders [Yahoo! Finance]
Low
Report
What Disc Medicine (IRON)'s Bitopertin Fast-Track Review and Rising R&D Spend Mean for Shareholders [Yahoo! Finance]
11/6
08:30 am
iron
Disc Medicine Reports Third Quarter 2025 Financial Results and Provides Business Update
Low
Report
Disc Medicine Reports Third Quarter 2025 Financial Results and Provides Business Update
11/3
09:00 am
iron
Disc Medicine Announces Presentation of Initial Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 67th American Society of Hematology (ASH) Annual Meeting
Low
Report
Disc Medicine Announces Presentation of Initial Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 67th American Society of Hematology (ASH) Annual Meeting
11/3
08:03 am
iron
Disc Medicine (NASDAQ:IRON) had its "buy" rating reaffirmed by analysts at Stifel Nicolaus. They now have a $125.00 price target on the stock.
Low
Report
Disc Medicine (NASDAQ:IRON) had its "buy" rating reaffirmed by analysts at Stifel Nicolaus. They now have a $125.00 price target on the stock.
10/31
08:30 am
iron
Disc Medicine to Participate in Upcoming Investor Conferences
Low
Report
Disc Medicine to Participate in Upcoming Investor Conferences
10/30
02:19 pm
iron
Disc Medicine (NASDAQ:IRON) had its price target raised by analysts at Morgan Stanley from $90.00 to $115.00. They now have an "overweight" rating on the stock.
Low
Report
Disc Medicine (NASDAQ:IRON) had its price target raised by analysts at Morgan Stanley from $90.00 to $115.00. They now have an "overweight" rating on the stock.
10/21
12:14 am
iron
Disc Medicine Announces Pricing of $250 Million Upsized Public Offering of Common Stock and Pre-Funded Warrants
Low
Report
Disc Medicine Announces Pricing of $250 Million Upsized Public Offering of Common Stock and Pre-Funded Warrants
10/20
07:00 am
iron
Disc Medicine Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Low
Report
Disc Medicine Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
10/20
06:30 am
iron
Disc Medicine Provides Update on Hematology Portfolio and Outlines Near-Term Business Objectives and Anticipated Milestones
Low
Report
Disc Medicine Provides Update on Hematology Portfolio and Outlines Near-Term Business Objectives and Anticipated Milestones
10/18
09:34 pm
iron
Why Disc Medicine (IRON) Is Up 28.7% After Securing FDA Priority Review for Bitopertin Accelerated Approval [Yahoo! Finance]
Medium
Report
Why Disc Medicine (IRON) Is Up 28.7% After Securing FDA Priority Review for Bitopertin Accelerated Approval [Yahoo! Finance]
10/17
11:00 am
iron
Disc Medicine (NASDAQ:IRON) was given a new $153.00 price target on by analysts at National Bankshares, Inc..
Low
Report
Disc Medicine (NASDAQ:IRON) was given a new $153.00 price target on by analysts at National Bankshares, Inc..
10/17
10:47 am
iron
Disc Medicine (NASDAQ:IRON) had its price target raised by analysts at Cantor Fitzgerald from $132.00 to $153.00. They now have an "overweight" rating on the stock.
Low
Report
Disc Medicine (NASDAQ:IRON) had its price target raised by analysts at Cantor Fitzgerald from $132.00 to $153.00. They now have an "overweight" rating on the stock.